Wells Fargo raised the firm’s price target on Cerevel Therapeutics (CERE) to $45 from $30 and keeps an Equal Weight rating on the shares. The firm cites AbbVie’s (ABBV) announcement that it will acquire Cerevel for $8.7B or $45 per share. The deal is expected to close mid-2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CERE:
- Cerevel Therapeutics downgraded to Hold from Buy at Jefferies
- Cerevel Therapeutics just downgraded at Stifel, here’s why
- Cerevel Therapeutics downgraded to Hold from Buy at Stifel
- The biopharma stocks to own in 2024, according to Morgan Stanley
- Cerevel Therapeutics to host conference call
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue